Ascendis Pharma A/S’s (ASND) “Outperform” Rating Reaffirmed at Wedbush

Wedbush reaffirmed their outperform rating on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a report released on Tuesday,Benzinga reports. The firm currently has a $220.00 target price on the biotechnology company’s stock. Wedbush also issued estimates for Ascendis Pharma A/S’s Q4 2025 earnings at $0.23 EPS, FY2025 earnings at ($3.49) EPS and FY2026 earnings at $2.43 EPS.

ASND has been the topic of several other reports. Wolfe Research initiated coverage on Ascendis Pharma A/S in a research report on Tuesday. They issued a “peer perform” rating and a $255.00 target price on the stock. Raymond James Financial initiated coverage on shares of Ascendis Pharma A/S in a report on Friday, October 17th. They issued a “strong-buy” rating and a $271.00 price objective on the stock. Wall Street Zen lowered shares of Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research note on Saturday. Stifel Nicolaus upped their target price on shares of Ascendis Pharma A/S from $212.00 to $254.00 and gave the stock a “buy” rating in a research report on Friday, August 8th. Finally, JPMorgan Chase & Co. raised their price target on shares of Ascendis Pharma A/S from $260.00 to $264.00 and gave the company an “overweight” rating in a research note on Thursday, October 9th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Ascendis Pharma A/S presently has an average rating of “Moderate Buy” and a consensus price target of $256.60.

Ascendis Pharma A/S Stock Up 0.3%

Shares of ASND stock opened at $217.13 on Tuesday. The company has a market cap of $13.40 billion, a P/E ratio of -42.08 and a beta of 0.44. The business has a 50 day moving average of $202.37 and a two-hundred day moving average of $185.47. Ascendis Pharma A/S has a 52 week low of $118.03 and a 52 week high of $223.18.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings results on Wednesday, November 12th. The biotechnology company reported ($1.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.76). The firm had revenue of $290.24 million during the quarter, compared to analyst estimates of $246.91 million. Analysts expect that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Institutional Investors Weigh In On Ascendis Pharma A/S

A number of institutional investors and hedge funds have recently modified their holdings of ASND. Advisory Services Network LLC acquired a new position in shares of Ascendis Pharma A/S in the 3rd quarter valued at $26,000. Compagnie Lombard Odier SCmA purchased a new stake in Ascendis Pharma A/S during the second quarter valued at about $39,000. First Horizon Advisors Inc. acquired a new position in shares of Ascendis Pharma A/S in the second quarter worth about $41,000. Jones Financial Companies Lllp increased its position in shares of Ascendis Pharma A/S by 57.2% in the third quarter. Jones Financial Companies Lllp now owns 228 shares of the biotechnology company’s stock worth $44,000 after acquiring an additional 83 shares in the last quarter. Finally, Brooklyn Investment Group raised its holdings in shares of Ascendis Pharma A/S by 332.9% during the first quarter. Brooklyn Investment Group now owns 355 shares of the biotechnology company’s stock valued at $55,000 after acquiring an additional 273 shares during the period.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.